School of Pharmaceutical Science and Technology, Tianjin University, No.92 Weijin Road, Nankai District, Tianjin, 300072, People's Republic of China,
Eur J Clin Pharmacol. 2014 Apr;70(4):479-82. doi: 10.1007/s00228-014-1643-8. Epub 2014 Jan 21.
Ibuprofen and acetaminophen are frequently alternated or simultaneously used to treat fever or pain in children, while the evidence for the safety of such a combination is lacking. In this study, we analyzed the association of acute kidney injury (AKI) with ibuprofen, acetaminophen, and the combination of both drugs in children (0-12 years) by using the FDA Adverse Event Reporting System (AERS) database between January 2004 and June 2012.
Adverse event reports in children aged 0 to ≤12 years were included in the study. Cases were defined as reports of AKI according to the Medical Dictionary for Regulatory Activities (MedDRA) terminology, non-cases as all other reports. Exposure categories were divided into three index groups: two groups where ibuprofen or acetaminophen were used in absence of one another and another group where both drugs were used concomitantly. There was also a reference group, in which neither ibuprofen nor acetaminophen was used. These index groups were compared with the reference group using reporting odds ratios (RORs).
In total, 47,803 reports were included in the study. After adjusting for year of reporting, age, and sex, the ROR for an AKI in children who used only ibuprofen or acetaminophen compared with children who used neither ibuprofen nor acetaminophen was 2.14 (95 % CI: 1.59-2.88) and 1.53 (95 % CI: 1.18-1.97), respectively, while the adjusted ROR was 4.01 (95 % CI: 2.96-5.43) when both drugs were concomitantly used.
The results illustrate that the concomitant use of ibuprofen and acetaminophen in children might be associated with increased risk of AKI.
布洛芬和对乙酰氨基酚常用于交替或同时治疗儿童发热或疼痛,但缺乏联合使用这两种药物的安全性证据。本研究利用美国食品药品监督管理局不良事件报告系统(AERS)数据库,分析了 2004 年 1 月至 2012 年 6 月期间 0-12 岁儿童使用布洛芬、对乙酰氨基酚及两者联合用药与急性肾损伤(AKI)的关联性。
本研究纳入了 0-12 岁儿童的不良事件报告。根据监管活动医学词典(MedDRA)术语,将 AKI 定义为病例,其他报告则定义为非病例。暴露类别分为三组索引组:两组分别为单独使用布洛芬或对乙酰氨基酚而无另一药物的使用,以及一组同时使用两种药物。还有一组参照组,两种药物均未使用。使用报告比值比(ROR)将这些索引组与参照组进行比较。
本研究共纳入 47803 例报告。在调整报告年份、年龄和性别后,与未使用布洛芬和对乙酰氨基酚的儿童相比,单独使用布洛芬或对乙酰氨基酚的儿童发生 AKI 的 ROR 分别为 2.14(95%可信区间:1.59-2.88)和 1.53(95%可信区间:1.18-1.97),而同时使用两种药物时,调整后的 ROR 为 4.01(95%可信区间:2.96-5.43)。
结果表明,儿童同时使用布洛芬和对乙酰氨基酚可能与 AKI 风险增加相关。